Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Sevirumab (DVV05101)

Host species:Human
Isotype:IgG1, kappa
Applications:Research Grade Biosimilar
Expression system:Mammalian Cells
Overview

Catalog No.

DVV05101

Expression system

Mammalian Cells

Species reactivity

Human cytomegalovirus (HCMV/HHV-5)

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Target

Envelope glycoprotein H, gH, gH, UL75

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P12824

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

EV2 7, MSL 109, SDZ MSL 109, CAS: 138660-96-5

Clone ID

Sevirumab

Data Image
  • SDS-PAGE
    SDS PAGE for Sevirumab
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Sevirumab. Protovir, MSL 109, EV2 7, SDZ MSL 109, PMID: 10728470

Therapeutic developments in cytomegalovirus retinitis, PMID: 11060672

Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy, PMID: 11428987

Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109, PMID: 24843144

In vitro affinity maturation of a natural human antibody overcomes a barrier to in vivo affinity maturation, PMID: 24492299

Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy, PMID: 12523893

A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis, PMID: 15498605

HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial, PMID: 11919489

Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation, PMID: 11464977

Data and safety monitoring board deliberations resulting in the early termination of the Monoclonal Antibody Cytomegalovirus Retinitis Trial, PMID: 12559647

Datasheet

Document Download

Research Grade Sevirumab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Sevirumab [DVV05101]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2024 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only